Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Starts & Stops: Boston Scientific Starts, Stops, And Finishes TAVR Trials

Executive Summary

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This month's edition includes seven trial-terminations – not as many as last month, but more than usual – for a variety of reasons, including Boston Scientific's suspension of all its trials of the Lotus transcatheter aortic valve due to a manufacturing problem.

Advertisement

Related Content

Medtronic’s Solitaire Gets STRATIS Real-World Stroke Boost
Boston Scientific Pulls All Lotus TAVR Systems Off Shelves
Starts & Stops: Abbott's Inherited Products Add To Spike In Suspensions
Starts & Stops: S-ICD And Respiratory App Studies Among Year-End Large-Scale Trial Launches
Starts & Stops: Medtronic's Symplicity Flatlines For Heart Failure
Boston Sci's Watchman Gets Positive Medicare Coverage Policy
ICD Guidelines From ACC/AHA/NASPE Embrace MADIT-II Prophylactic Use

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT104584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel